January 04, 2019

Deal Snapshot: Bristol-Myers Squibb & Celgene

Bristol-Myers Squibb Logo

  • Deal Headline: Bristol-Myers Squibb to Acquire Celgene (3rd Jan 2019)
  • Deal Type: Acquisition
  • Acquirer: Bristol-Myers Squibb
  • Target: Celgene
  • Therapeutic Areas: Immuno-oncology, Oncology, Immunology
  • Cash-equivalent Value: $74B

Bristol-Myers Squibb Key BD Contacts

Bristol-Myers Squibb Deal Activity by Therapeutic Area (Last 3 Years)

33% Immuno-oncology, 33% Immunology, 21% Oncology, 13% Other

Recent deals:

Bristol-Myers Squibb Pipeline Composition

55% Oncology, 24% Immunology, 13% Cardiovascular, 8% Fibrotic Diseases


Business profiles tailored to your asset.